Method of treating sepsis by administering a soluble CD52 glycoprotein

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9778269
SERIAL NO

14440703

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present disclosure relates to the use of a soluble CD52 glycoprotein in treating diseases regulated by effector T-cells, for example sepsis or multiple sclerosis. The present disclosure also relates to diagnostic methods based on the detection of CD52 expression levels in a subject.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH1G ROYAL PARADE PARKVILLE MELBOURNE VICTORIA 3052 AUSTRALIA

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Harrison, Leonard Charles Melbourne, AU 10 15
Rashidi, Maryam Melbourne, AU 4 1
Zhang, Yuxia Melbourne, AU 11 6

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Apr 3, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 3, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00